Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APHATSE:GUDTSE:HLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHAAphria$15.38$15.48$2.78▼$32.29$4.87B2.6721.83 million shsN/AGUDKnight TherapeuticsC$6.05+0.5%C$5.89C$5.09▼C$6.45C$611.96M0.567,197 shs9,509 shsHLSHLS TherapeuticsC$4.94+0.8%C$4.78C$3.00▼C$5.23C$109.90M1.0713,547 shs6,301 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPHAAphria0.00%0.00%0.00%0.00%0.00%GUDKnight Therapeutics+0.50%+5.22%+3.95%+3.24%+5.22%HLSHLS Therapeutics+0.82%+3.13%+0.82%+15.69%+35.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPHAAphriaN/AN/AN/AN/AN/AN/AN/AN/AGUDKnight TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHLSHLS Therapeutics0.4536 of 5 stars1.00.01.70.00.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPHAAphria 0.00N/AN/AN/AGUDKnight Therapeutics 3.50Strong BuyC$7.1518.18% UpsideHLSHLS Therapeutics 2.00HoldC$4.50-8.91% DownsideCurrent Analyst Ratings BreakdownLatest GUD, EOF, HLS, and APHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025GUDKnight TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ BuyC$6.50(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPHAAphria$405.96M12.00$0.09 per share166.43$4.80 per share3.20GUDKnight TherapeuticsC$348.70M1.75C$1.57 per share3.85C$7.65 per share0.79HLSHLS TherapeuticsC$40.13M2.74C$0.32 per share15.22C$2.51 per share1.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPHAAphria-$63.21M-$0.06N/A219.71N/A-36.10%-2.30%-1.66%N/AGUDKnight Therapeutics-C$30.73M-C$0.30N/A∞N/A-8.81%-4.04%0.51%N/AHLSHLS Therapeutics-C$15.53M-C$1.00N/A∞N/A-38.70%-25.27%-2.89%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPHAAphriaN/AN/AN/AN/AN/AGUDKnight TherapeuticsN/AN/AN/AN/AN/AHLSHLS TherapeuticsC$0.204.05%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPHAAphria0.252.361.17GUDKnight Therapeutics7.523.361.79HLSHLS Therapeutics86.501.561.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPHAAphria10.30%GUDKnight Therapeutics12.58%HLSHLS Therapeutics65.20%Insider OwnershipCompanyInsider OwnershipAPHAAphriaN/AGUDKnight Therapeutics45.62%HLSHLS Therapeutics0.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPHAAphria1,200316.80 millionN/AOptionableGUDKnight Therapeutics725101.15 millionN/ANot OptionableHLSHLS Therapeutics9122.25 millionN/ANot OptionableGUD, EOF, HLS, and APHA HeadlinesRecent News About These CompaniesHLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia’s Provincial Drug PlanJuly 3 at 10:12 PM | cantechletter.comCHLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug PlanJuly 2 at 9:56 AM | finance.yahoo.comHLS Therapeutics Reports Annual Meeting ResultsJune 20, 2025 | finance.yahoo.comThe past five years for HLS Therapeutics (TSE:HLS) investors has not been profitableJune 20, 2025 | finance.yahoo.comHLS Therapeutics (TSE:HLS) Trading 1.8% Higher - Here's What HappenedJune 17, 2025 | marketbeat.comHLS Therapeutics First Quarter 2025 Earnings: EPS Misses ExpectationsMay 10, 2025 | finance.yahoo.comEarnings call transcript: HLS Therapeutics Q1 2025 results show mixed signalsMay 10, 2025 | uk.investing.comHLS Therapeutics Announces Q1 2025 Financial ResultsMay 10, 2025 | seekingalpha.comHLS Therapeutics Inc (HLS) Receives a Hold from Stifel NicolausMarch 14, 2025 | markets.businessinsider.comHLS Therapeutics Appoints Christine Elliott to its Board of DirectorsMarch 13, 2025 | finance.yahoo.comHLS Therapeutics Gets Green Light for Share Buyback ProgramMarch 13, 2025 | marketwatch.comTop Canadian Pharmaceutical Stocks of 2025February 3, 2025 | fool.caGLP-1 Drugs Could Help People With Alcohol Use DisorderNovember 13, 2024 | medpagetoday.comMOptimistic Buy Rating for HLS Therapeutics Despite Revenue ChallengesNovember 10, 2024 | markets.businessinsider.comHLS Therapeutics Third Quarter 2024 Earnings: Misses ExpectationsNovember 8, 2024 | finance.yahoo.comHLS Therapeutics Inc (HLTRF) Q3 2024 Earnings Call Highlights: Strategic Debt Reduction and ...November 8, 2024 | finance.yahoo.comHLS Therapeutics Inc (TSX:HLS) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 6, 2024 | finance.yahoo.comOctober Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’November 5, 2024 | stockhead.com.auSHLS Therapeutics Inc. (TSE:HLS) Shares Could Be 38% Below Their Intrinsic Value EstimateOctober 17, 2024 | finance.yahoo.comDantech Announces Participation as a Silver Sponsor at BioFuture 2024 in New York CityOctober 14, 2024 | finance.yahoo.comHarvard Business School Announces 2024-2025 Cohort of Executive FellowsOctober 11, 2024 | hbs.eduHNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGUD, EOF, HLS, and APHA Company DescriptionsAphria NASDAQ:APHAAphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.Knight Therapeutics TSE:GUDC$6.05 +0.03 (+0.50%) As of 07/4/2025 04:00 PM EasternKnight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.HLS Therapeutics TSE:HLSC$4.94 +0.04 (+0.82%) As of 07/4/2025 01:54 PM EasternHLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
